Susan Wu, PhD

Susan (Su) Wu is the Head of Development Operations and Program Management at Triveni Bio, where she is responsible for program management, clinical operations, and regulatory affairs. She has almost two decades of experience in drug development and regulatory science. Prior to joining Triveni, Su held a leadership role at Celsius Therapeutics where she brought their lead asset into early clinical testing and ultimately played an integral role in the company’s acquisition by Abbvie. In addition, Su spent over a decade at Vertex Pharmaceuticals working on multiple development programs and was instrumental in obtaining approvals for TRIKAFTA (KAFTRIO in EU) and ORKAMBI for the treatment of cystic fibrosis. Su earned her PhD in Biochemistry and Biophysics from the University of North Carolina, Chapel Hill and BS in Biology from Tufts University.